Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...
Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, Wynn, HP Inc., Acadia Healthcare, and More
Stocks traded mixed Friday after the Federal Reserve’s preferred inflation measure, the personal consumption expenditures ...
The FDA just approved Bristol Myers Squibb's groundbreaking schizophrenia treatment
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The ...
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
Bristol-Myers Squibb stock jumps on schizophrenia drug approval
Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...
Bristol Myers wins US FDA approval for new type of schizophrenia drug
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
Wall Street Breakfast Podcast: Bristol-Myers Wins FDA Nod For Novel Antipsychotic
Bristol-Myers wins FDA nod for novel antipsychotic. DirecTV, Dish close in on merger to form largest US pay-TV service: ...
Bristol-Myers Stock Jumps on FDA Approval for New Schizophrenia Drug
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the ...
Bristol-Myers Squibb: Hold Rating Amid New Schizophrenia Drug Launch and Patent Expiries
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...